Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lemonde, H A
Right arrow Articles by Clayton, P T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lemonde, H A
Right arrow Articles by Clayton, P T
Gut 2003;52:1494-1499
© 2003 by BMJ Publishing Group Ltd & British Society of Gastroenterology


LIVER

Mutations in SRD5B1 (AKR1D1), the gene encoding {Delta}4-3-oxosteroid 5ß-reductase, in hepatitis and liver failure in infancy

H A Lemonde1, E J Custard2, J Bouquet3, M Duran4, H Overmars4, P J Scambler2, P T Clayton1

1 Biochemistry, Endocrinology, and Metabolism Unit, Institute of Child Health, University College London with Great Ormond Street Hospital for Children NHS Trust, London, UK
2 Molecular Medicine Unit, Institute of Child Health, University College London with Great Ormond Street Hospital for Children NHS Trust, London, UK
3 Erasmus MC/Sophia Children’s Hospital, Rotterdam, the Netherlands
4 Laboratory for Genetic Metabolic Diseases, Academic Medical Centre, Amsterdam, the Netherlands

Correspondence to:
Correspondence to:
Professor P T Clayton, Biochemistry, Endocrinology, and Metabolism Unit, Institute of Child Health, 30 Guilford St, London WC1N 1 EH, UK;
p.clayton{at}ich.ucl.ac.uk

Background: A substantial group of patients with cholestatic liver disease in infancy excrete, as the major urinary bile acids, the glycine and taurine conjugates of 7{alpha}-hydroxy-3-oxo-4-cholenoic acid and 7{alpha},12{alpha}-dihydroxy-3-oxo-4-cholenoic acid. It has been proposed that some (but not all) of these have mutations in the gene encoding {Delta}4-3-oxosteroid 5ß-reductase (SRD5B1; AKR1D1, OMIM 604741).

Aims: Our aim was to identify mutations in the SRD5B1 gene in patients in whom chenodeoxycholic acid and cholic acid were absent or present at low concentrations in plasma and urine, as these seemed strong candidates for genetic 5ß-reductase deficiency.

Patients and subjects: We studied three patients with neonatal onset cholestatic liver disease and normal {gamma}-glutamyl transpeptidase in whom 3-oxo-{Delta}4 bile acids were the major bile acids in urine and plasma and saturated bile acids were at low concentration or undetectable. Any base changes detected in SRD5B1 were sought in the parents and siblings and in 50 ethnically matched control subjects.

Methods: DNA was extracted from blood and the nine exons of SRD5B1 were amplified and sequenced. Restriction enzymes were used to screen the DNA of parents, siblings, and controls.

Results: Mutations in the SRD5B1 gene were identified in all three children. Patient MS was homozygous for a missense mutation (662 C>T) causing a Pro198Leu amino acid substitution; patient BH was homozygous for a single base deletion (511 delT) causing a frame shift and a premature stop codon in exon 5; and patient RM was homozygous for a missense mutation (385 C>T) causing a Leu106Phe amino acid substitution. All had liver biopsies showing a giant cell hepatitis; in two, prominent extramedullary haemopoiesis was noted. MS was cured by treatment with chenodeoxycholic acid and cholic acid; BH showed initial improvement but then deteriorated and required liver transplantation; RM had advanced liver disease when treatment was started and also progressed to liver failure.

Conclusions: Analysis of blood samples for SRD5B1 mutations can be used to diagnose genetic 5ß-reductase deficiency and distinguish these patients from those who have another cause of 3-oxo-{Delta}4 bile aciduria, for example, severe liver damage. Patients with genetic 5ß-reductase deficiency may respond well to treatment with chenodeoxycholic acid and cholic acid if liver disease is not too advanced.


Keywords: bile acid synthesis; inborn error; giant cell hepatitis; cholestasis; bile acid treatment

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; {gamma}-GT, {gamma}-glutamyl transpeptidase; ALP, alkaline phosphatase; APTT, activated partial thromboplastin time; LSIMS, liquid secondary ionisation mass spectrometry; ESI-MS/MS, electrospray ionisation tandem mass spectrometry; PCR, polymerase chain reaction; GC-MS, gas chromatography-mass spectrometry; BSEP, bile acid export pump; FXR, farnesoid X receptor




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
L. Di Costanzo, J. E. Drury, T. M. Penning, and D. W. Christianson
Crystal Structure of Human Liver {Delta}4-3-Ketosteroid 5{beta}-Reductase (AKR1D1) and Implications for Substrate Binding and Catalysis
J. Biol. Chem., June 13, 2008; 283(24): 16830 - 16839.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
N. C. Andrews, S. Anupindi, and K. Badizadegan
Case 21-2005 - A Four-Week-Old Male Infant with Jaundice and Thrombocytopenia
N. Engl. J. Med., July 14, 2005; 353(2): 189 - 198.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2003 BMJ Publishing Group Ltd & British Society of Gastroenterology